ALX2004 vs Erlotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
ALX2004
Developed by ALX Oncology Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07085091 (registry estimate)
No aligned efficacy figure on record for this race.
Erlotinib
Rights held by Cheplapharm Arzneimittel GmbH and partners
NCT00446225 · Phase 3 · completed
EURTAC was a randomized, open-label Phase 3 in 174 patients with EGFR-mutant advanced NSCLC comparing erlotinib with platinum-based chemotherapy. Its primary endpoint, progression-free survival, is a clinical outcome and was met (HR 0.42). An open-label trial is never graded strong under the rubric.
Next expected readout: December 2027 · NCT04449874 (registry estimate)
Reported efficacy
Progression Free-survival (From the date of randomization to the date of last follow up, assessed up to 24 months): Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results). (met)
Result source: NCT00446225
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALX2004 | Erlotinib |
|---|---|---|
| PFS, median | —Not reported | 7.6 vs 6+1.6 vs placeboNCT008837797 other results
|
| OS, median | —Not reported | 11.9 vs 10.2vs Standard of CareNCT0135141511 other results
|
| ORR | —Not reported | 42.9% vs 17.8%+25.1 vs placeboNCT0088377923 other results
|
| Duration of response, median | —Not reported | 10.3 vs 5.6+4.7 vs placeboNCT008837793 other results
|
PFS, median
- ALX2004
- —Not reported
- Erlotinib
- 7.6 vs 6+1.6 vs placeboNCT00883779
7 other results
- 4.8 vs 3.7 NCT00257608
- 5.4 vs 8.0 NCT00531960
- 5.6 vs 5.4 NCT00518011
- 6.7 NCT00800202
- 6.3 NCT00800202
- 24.5 vs 9.9 NCT02039674
- 7.0 vs 5.4 NCT01998919
OS, median
- ALX2004
- —Not reported
- Erlotinib
- 11.9 vs 10.2vs Standard of CareNCT01351415
11 other results
- 14.4 vs 13.3 NCT00257608
- 34.5 vs 21.1 NCT02039674
- 17.1 vs 17.5 NCT01998919
- 16.4 NCT00531960
- 9 vs 4.9 NCT00518011
- 12.5 NCT00550537
- 17.2 NCT00550537
- 6.1 NCT00550537
- 16 NCT00800202
- 12 NCT00800202
- 9 NCT00701558
ORR
- ALX2004
- —Not reported
- Erlotinib
- 42.9% vs 17.8%+25.1 vs placeboNCT00883779
23 other results
- 8.6% vs 6.3% NCT01351415
- 55% vs 28.6% NCT02039674
- 29.5% NCT02039674
- 15.8% NCT00701558
- 36.8% vs 24.4% NCT01998919
- 27% vs 44.3% NCT00531960
- 28.6% vs 0% NCT00518011
- 62.7% NCT00800202
- 12.5% NCT00800202
- 23.1% NCT01454102
- 38.5% NCT01454102
- 41.7% NCT01454102
- 46.7% NCT01454102
- 46.7% NCT01454102
- 16.7% NCT01454102
- 19% NCT01454102
- 20.8% NCT01454102
- 24% NCT01454102
- 32.5% NCT01454102
- 47.4% NCT01454102
- 8.3% NCT01454102
- 22.6% NCT01454102
- 50% NCT01454102
Duration of response, median
- ALX2004
- —Not reported
- Erlotinib
- 10.3 vs 5.6+4.7 vs placeboNCT00883779
3 other results
- 7.5 vs 6.2 NCT01351415
- 8.9 vs 5.6 NCT01998919
- 3.8 NCT00518011
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALX2004: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ALX2004: 0 of 4 rows · Erlotinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Erlotinib |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT01351415 · Phase 3 · registry result, not featured evidence · combination show 42 more results38.1% NCT00883779 · Phase 3 · registry result, not featured evidence — NCT00257608 · Phase 3 · registry result, not featured evidence · combination 5.5% NCT00621049 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneBevacizumab+Erlotinib NCT00800202 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneBevacizumab+Paclitaxel+Carboplatin NCT00800202 · Phase 2 · registry result, not featured evidence · combination 47.3% NCT01998919 · Phase 2 · registry result, not featured evidence · combination 78.9% NCT00701558 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT00531960 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT00518011 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestonePart 2 Cohort G+ (Pembro 200 mg+Pe NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort B10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort C10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort D1 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort D2 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Part 1 Cohort A2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort B2 (Pembro 2mg/kg+Pa NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort C2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort D4 (Pembro 2 mg/kg+I NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort E (Pembro 2 mg/kg+Er NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort F (Pembro 2 mg/kg+Ge NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 2 Cohort H (Pembro 2mg/kg+I) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Part 1 Cohort A10 (Pembro10mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Arm A: Nivolumab + Gemcitabine + C NCT01454102 · Phase 1 · registry result, not featured evidence · combination 0%Arm B: Nivolumab + Pemetrexed + Ci NCT01454102 · Phase 1 · registry result, not featured evidence · combination 0%Arm C10: Nivolumab + Paclitaxel + NCT01454102 · Phase 1 · registry result, not featured evidence · combination 7.1%Arm C5: Nivolumab + Paclitaxel + C NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm C: Nivolumab + Paclitaxel + Ca NCT01454102 · Phase 1 · registry result, not featured evidence · combination 0%Arm D: Nivolumab + Bevacizumab Mai NCT01454102 · Phase 1 · registry result, not featured evidence · combination 14.3%Arm E: Nivolumab + Erlotinib NCT01454102 · Phase 1 · registry result, not featured evidence · combination 5.8%Arm F: Nivolumab NCT01454102 · Phase 1 · registry result, not featured evidence —Arm G: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 8.3%Arm GH: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm H: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm I: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 0%Arm IJ: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm J: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 0%Arm M: Nivolumab NCT01454102 · Phase 1 · registry result, not featured evidence 12.9%Arm N: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 17.5%Arm O: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 10.5%Arm P: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 7.7%Arm Q: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT01351415 · Phase 3 · registry result, not featured evidence · combination show 42 more results7.1% NCT00883779 · Phase 3 · registry result, not featured evidence — NCT00257608 · Phase 3 · registry result, not featured evidence · combination — NCT00621049 · Phase 2 · registry result, not featured evidence 25%Bevacizumab+Erlotinib NCT00800202 · Phase 2 · registry result, not featured evidence · combination 10.4%Bevacizumab+Paclitaxel+Carboplatin NCT00800202 · Phase 2 · registry result, not featured evidence · combination 6.8% NCT01998919 · Phase 2 · registry result, not featured evidence · combination — NCT00701558 · Phase 2 · registry result, not featured evidence · combination 6.3% NCT00531960 · Phase 2 · registry result, not featured evidence · combination 37.5% NCT00518011 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy 3.3%Part 2 Cohort G+ (Pembro 200 mg+Pe NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 7.7%Part 1 Cohort B10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort C10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort D1 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort D2 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Part 1 Cohort A2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort B2 (Pembro 2mg/kg+Pa NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort C2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 8.3%Part 1 Cohort E (Pembro 2 mg/kg+Er NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort F (Pembro 2 mg/kg+Ge NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 3%Part 2 Cohort H (Pembro 2mg/kg+I) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Part 1 Cohort A10 (Pembro10mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Arm A: Nivolumab + Gemcitabine + C NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm B: Nivolumab + Pemetrexed + Ci NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm C10: Nivolumab + Paclitaxel + NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm C5: Nivolumab + Paclitaxel + C NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm C: Nivolumab + Paclitaxel + Ca NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm D: Nivolumab + Bevacizumab Mai NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm E: Nivolumab + Erlotinib NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm F: Nivolumab NCT01454102 · Phase 1 · registry result, not featured evidence —Arm G: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm GH: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm H: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm I: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm IJ: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm J: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm M: Nivolumab NCT01454102 · Phase 1 · registry result, not featured evidence —Arm N: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm O: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm P: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm Q: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 51.9%a NCT01351415 · Phase 3 · registry result, not featured evidence · combination show 42 more results31% NCT00883779 · Phase 3 · registry result, not featured evidence 23.4% NCT00257608 · Phase 3 · registry result, not featured evidence · combination 25.5% NCT00621049 · Phase 2 · registry result, not featured evidence 29.2%Bevacizumab+Erlotinib NCT00800202 · Phase 2 · registry result, not featured evidence · combination 40.3%Bevacizumab+Paclitaxel+Carboplatin NCT00800202 · Phase 2 · registry result, not featured evidence · combination 23% NCT01998919 · Phase 2 · registry result, not featured evidence · combination 10.5% NCT00701558 · Phase 2 · registry result, not featured evidence · combination 27% NCT00531960 · Phase 2 · registry result, not featured evidence · combination 75% NCT00518011 · Phase 2 · registry result, not featured evidence · combination 25%200 mg NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy 50.8%Part 2 Cohort G+ (Pembro 200 mg+Pe NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 61.5%Part 1 Cohort B10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 58.3%Part 1 Cohort C10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 1 Cohort D1 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 1 Cohort D2 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 53.8%Part 1 Cohort A2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 72.7%Part 1 Cohort B2 (Pembro 2mg/kg+Pa NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 50%Part 1 Cohort C2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 41.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 66.7%Part 1 Cohort E (Pembro 2 mg/kg+Er NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 71.4%Part 1 Cohort F (Pembro 2 mg/kg+Ge NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 36.4%Part 2 Cohort H (Pembro 2mg/kg+I) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 41.7%Part 1 Cohort A10 (Pembro10mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Arm A: Nivolumab + Gemcitabine + C NCT01454102 · Phase 1 · registry result, not featured evidence · combination 66.7%Arm B: Nivolumab + Pemetrexed + Ci NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm C10: Nivolumab + Paclitaxel + NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm C5: Nivolumab + Paclitaxel + C NCT01454102 · Phase 1 · registry result, not featured evidence · combination 58.6%Arm C: Nivolumab + Paclitaxel + Ca NCT01454102 · Phase 1 · registry result, not featured evidence · combination 25%Arm D: Nivolumab + Bevacizumab Mai NCT01454102 · Phase 1 · registry result, not featured evidence · combination 52.4%Arm E: Nivolumab + Erlotinib NCT01454102 · Phase 1 · registry result, not featured evidence · combination 44.2%Arm F: Nivolumab NCT01454102 · Phase 1 · registry result, not featured evidence 66.7%Arm G: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm GH: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 80%Arm H: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 55.6%Arm I: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination —Arm IJ: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 75%Arm J: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 33.3%Arm M: Nivolumab NCT01454102 · Phase 1 · registry result, not featured evidence 38.7%Arm N: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 52.5%Arm O: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 65.8%Arm P: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination 64.1%Arm Q: Nivolumab + Ipilimumab NCT01454102 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a diarrhoea 37% nausea 34.6% decreased appetite 34.2% NCT01351415 · Phase 3 · registry result, not featured evidence · combination show 38 more resultsrash 62.8% (placebo 32.4%) neutropenia 50.4% (placebo 49.5%) nausea 39.8% (placebo 41.4%) NCT00883779 · Phase 3 · registry result, not featured evidence rash 55.4% (placebo 18.8%) diarrhoea 51.1% (placebo 19.6%) fatigue 34.2% (placebo 24.8%) NCT00257608 · Phase 3 · registry result, not featured evidence · combination fatigue 67.3% nausea 58.2% diarrhea 47.3% NCT00621049 · Phase 2 · registry result, not featured evidence asthenia 62.5% diarrhoea 62.5% folliculitis 45.8% NCT00800202 · Phase 2 · registry result, not featured evidence · combination asthenia 71.6% hypertension 52.2% neutropenia 49.3% NCT00800202 · Phase 2 · registry result, not featured evidence · combination rash 64.9% (placebo 40.5%) nausea 45.9% (placebo 46.8%) decreased appetite 40.5% (placebo 41.8%) NCT01998919 · Phase 2 · registry result, not featured evidence · combination anaemia of malignant disease 36.8% thrombocytopenia 31.6% rash 15.8% NCT00701558 · Phase 2 · registry result, not featured evidence · combination rash 61.9% diarrhoea 42.9% cough 30.2% NCT00531960 · Phase 2 · registry result, not featured evidence · combination rash 87.5% diarrhoea 75% anorexia 62.5% NCT00518011 · Phase 2 · registry result, not featured evidence · combination 200 mg decreased appetite 32.1% (placebo 27.4%) fatigue 25% (placebo 58.1%) cough 21.4% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy nausea 72.9% (placebo 59.7%) fatigue 69.5% (placebo 58.1%) constipation 54.2% (placebo 40.3%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination alopecia 61.5% (placebo 3.2%) cough 53.8% (placebo 27.4%) decreased appetite 53.8% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination fatigue 91.7% (placebo 58.1%) constipation 58.3% (placebo 40.3%) anaemia 50% (placebo 58.1%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination fatigue 100% (placebo 58.1%) actinic keratosis 33.3% (placebo 1.6%) back pain 33.3% (placebo 12.9%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination arthralgia 66.7% (placebo 29%) chills 66.7% (placebo 4.8%) cough 66.7% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 61.5% (placebo 40.3%) fatigue 61.5% (placebo 58.1%) alopecia 53.8% (placebo 3.2%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 81.8% (placebo 40.3%) alopecia 72.7% (placebo 3.2%) fatigue 72.7% (placebo 58.1%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 66.7% (placebo 40.3%) nausea 58.3% (placebo 59.7%) fatigue 50% (placebo 58.1%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 41.7% (placebo 40.3%) vomiting 41.7% (placebo 32.3%) cough 33.3% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 66.7% (placebo 30.6%) fatigue 58.3% (placebo 58.1%) cough 50% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 57.1% (placebo 30.6%) pruritus 42.9% (placebo 11.3%) rash 28.6% (placebo 16.1%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination fatigue 48.5% (placebo 58.1%) constipation 27.3% (placebo 40.3%) arthralgia 24.2% (placebo 29%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination fatigue 66.7% (placebo 58.1%) alopecia 58.3% (placebo 3.2%) constipation 58.3% (placebo 40.3%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 83.3% fatigue 83.3% anaemia 66.7% NCT01454102 · Phase 1 · registry result, not featured evidence · combination fatigue 93.3% nausea 80% decreased appetite 60% NCT01454102 · Phase 1 · registry result, not featured evidence · combination fatigue 79.3% alopecia 51.7% constipation 51.7% NCT01454102 · Phase 1 · registry result, not featured evidence · combination cough 58.3% fatigue 50% dyspnoea 41.7% NCT01454102 · Phase 1 · registry result, not featured evidence · combination fatigue 76.2% rash 61.9% diarrhoea 47.6% NCT01454102 · Phase 1 · registry result, not featured evidence · combination cough 53.8% fatigue 53.8% constipation 32.7% NCT01454102 · Phase 1 · registry result, not featured evidence decreased appetite 66.7% diarrhoea 44.4% fatigue 44.4% NCT01454102 · Phase 1 · registry result, not featured evidence · combination fatigue 73.3% diarrhoea 66.7% cough 40% NCT01454102 · Phase 1 · registry result, not featured evidence · combination fatigue 66.7% cough 33.3% decreased appetite 33.3% NCT01454102 · Phase 1 · registry result, not featured evidence · combination fatigue 68.8% decreased appetite 50% nausea 50% NCT01454102 · Phase 1 · registry result, not featured evidence · combination fatigue 58.3% cough 41.7% constipation 25% NCT01454102 · Phase 1 · registry result, not featured evidence fatigue 51.6% dyspnoea 41.9% cough 35.5% NCT01454102 · Phase 1 · registry result, not featured evidence · combination rash 35% diarrhoea 32.5% fatigue 32.5% NCT01454102 · Phase 1 · registry result, not featured evidence · combination pruritus 42.1% fatigue 36.8% cough 34.2% NCT01454102 · Phase 1 · registry result, not featured evidence · combination fatigue 46.2% decreased appetite 35.9% cough 33.3% NCT01454102 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Erlotinib
show 6 more results
show 5 more results
show 5 more results
show 3 more results
show 2 more results
show 5 more results
show 1 more result
+ 17 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALX2004's landscape · Erlotinib's landscape